ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1417

Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes

Giulia Marucci1, Ivan Caiello2, Manuela Pardeo1, Virginia Messia1, Giusi Prencipe1, Antonia Pascarella1, Fabrizio De Benedetti3 and Claudia Bracaglia1, 1Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, 3IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biomarkers, chemokines, inflammation and macrophage activation syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Increased ferritin is considered biomarker highly suggestive of primary and secondary HLH and it is one of the HLH-2004 diagnostic and MAS guidelines (1,2), nevertheless it could also be elevated in other inflammatory conditions. Interferon-gamma (IFNγ) and IFNγ-induced chemokines, particularly CXCL9, have been demonstrated to be markedly elevated in patients with primary and secondary HLH.

Methods: We describe eight patients with hyperferritinemia who fully or partially met the HLH-2004 diagnostic guideline, but in which the subsequent clinical course and further investigations led to different diagnosis that required different therapies and to investigate the CXCL9 levels in identify diseases that may mimic HLH. To be noted that soluble CD25 was not measured in these patients. Serum CXCL9 levels were analyzed by DuoSet ELISA KIT DY392 (R&D Systems, Minneapolis, Minn). Normal values of CXCL9 are lower than 700 pg/ml.

Results: We identified 8 patients with laboratory features suggestive of HLH, included high ferritin levels (>500 ng/ml). Three of these patients met five of the HLH-2004 criteria, two of them met four criteria and the others two met three criteria. One patient presented only high serum ferritin level and cytopenia. CXCL9 levels were <300 pg/ml in seven of them and approximately 600 pg/ml in one patient. The clinical disease course and the other investigations ruled out the diagnosis of HLH and every patient received a different diagnosis. None of them received treatment for HLH (Table 1).

Table 1. Patients’ features

Pt Gender Months at onset HLH-2004 Criteria Ferritin ng/ml CXCL9 pg/ml Final diagnosis
1 M 1 5 9.849 <300
Osteopetrosis
2 M 6 5 800 <300
Vitamin B12 deficiency
3 M 1 5 543 <300
Chronic granulomatous disease
4 M 1 4 15.629 <600
Short bowel syndrome
5 M 3 4 4.378 <300
Cobalamin deficiency
6 F 2 3 37.232 656
Shaken baby syndrome
7 M 165 3 1.400 <300
Ghosal hematodiaphyseal dysplasia
8 M 172 2 1.184 <300
Primitive myelofibrosis

Conclusion: Since HLH is a life-threatening condition, early recognition and promptly therapy are essential to modify the disease course. One of the most typical feature of primary and secondary HLH is high ferritin level. Due to the severity of the disease, sometimes patients need to be treated before all criteria are fulfilled. The eight patients reported had features highly suggestive of HLH and met the HLH-2004 criteria, or part of them. However they all received a different final diagnosis. Despite all presented with high ferritin levels, CXL9 was low in all. CXCL9 is a chemokine specifically induced by IFNγ, and has been demonstrated to be markedly elevated in patients with primary and secondary HLH due to the activation of the IFNγ pathway. In these cases CXCL9 was able to differentiate diseases with high ferritin that mimics HLH. High CXCL9 levels appear to be a potential specific biomarker for HLH diagnosis. Early dosage of CXCL9 levels in patients with hyperferritinemia and with clinical suspicion of HLH may be helpful for a timely differential diagnosis.

Reference

  1. Henter JI et al. Pediatr Blood Cancer 2007 Feb; 48(2):124-31.
  2. Ravelli A et al.Ann Rheum Dis. 2016 Mar;75(3):481-9.

Disclosure: G. Marucci, None; I. Caiello, None; M. Pardeo, None; V. Messia, None; G. Prencipe, None; A. Pascarella, None; F. De Benedetti, Abbvie, Sobi, Novimmune, Roche, Novartis, Sanofi, UCB, Pzifer, 2; C. Bracaglia, None.

To cite this abstract in AMA style:

Marucci G, Caiello I, Pardeo M, Messia V, Prencipe G, Pascarella A, De Benedetti F, Bracaglia C. Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/hemophagocytic-lymphohistiocytosis-hlh-mimickers-cxcl9-as-a-potential-biomarker-distinguishing-hlh-from-other-hyperferritinemic-syndromes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hemophagocytic-lymphohistiocytosis-hlh-mimickers-cxcl9-as-a-potential-biomarker-distinguishing-hlh-from-other-hyperferritinemic-syndromes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology